Education
About Us
Working with TipRanks
Follow Us
Elevance Health (ELV)
NYSE:ELV
ELV Analyst Ratings
Moderate Buy
13 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ELV Stock 12 Month Forecast
Average Price Target
$376.24
▲(7.65% Upside)
| Highest Price Target$425.00 | Average Price Target$376.24 | Lowest Price Target$310.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bernstein
$445→$420
Buy
20.18%
Upside
Reiterated
10/16/25
Morgan Stanley
$316→$359
Hold
2.72%
Upside
Reiterated
10/14/25
Truist Financial
$365→$400
Buy
14.45%
Upside
Reiterated
10/14/25
Goldman Sachs
$343
-1.86%
Downside
Initiated
10/14/25
Cantor Fitzgerald
$400
Buy
14.45%
Upside
Reiterated
10/10/25
Bank of America Securities
$330→$370
Hold
5.87%
Upside
Reiterated
10/10/25
Barclays
$373→$395
Buy
13.02%
Upside
Reiterated
10/09/25
Mizuho Securities
$342→$420
Buy
20.18%
Upside
Reiterated
10/08/25
Guggenheim
$360→$398
Buy
13.88%
Upside
Reiterated
10/08/25
Wells Fargo
$330→$412
Buy
17.89%
Upside
Reiterated
10/06/25
TR | OpenAI - 4o
$342→$349
Buy
-0.14%
Downside
Reiterated
09/19/25
AI Generated ArticleAI Generated Article
TD Cowen
$315.77→$330
Buy
-5.58%
Downside
Reiterated
09/18/25
UBS
$425
Buy
21.61%
Upside
Reiterated
09/08/25
Elevance Health: Positive Outlook with Strategic Pricing and Growth Opportunities Justify Buy RatingWe had a chance to catch up with ELV following the company's commentary at an investor conference on 9/4 (our note here). Regarding the nonrecurring items being reported in 2025 EPS, ELV provided a general sizing of each of the components. A favorable tax item to be recorded in the 4th quarter of this year is the largest unusual item and represents more than $1 of EPS. The VBC provider settlement, which was booked in 2Q25, is sized at around $0.70, while an investment income benefit booked in 1Q25 contributes another $0.30. There is also some operating expense favorability that is not expected to recur in 2026. Altogether, these components lead to an EPS benefit in the high $2 range and rounds roughly to $3. Separate from this, the company noted incentive comp is expected to be a slight headwind for 2026 relative to where 2025 will ultimately land.
Robert W. Baird
―
Hold
―
Reiterated
08/14/25
J.P. Morgan
$472→$384
Buy
9.87%
Upside
Reiterated
07/22/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bernstein
$445→$420
Buy
20.18%
Upside
Reiterated
10/16/25
Morgan Stanley
$316→$359
Hold
2.72%
Upside
Reiterated
10/14/25
Truist Financial
$365→$400
Buy
14.45%
Upside
Reiterated
10/14/25
Goldman Sachs
$343
-1.86%
Downside
Initiated
10/14/25
Cantor Fitzgerald
$400
Buy
14.45%
Upside
Reiterated
10/10/25
Bank of America Securities
$330→$370
Hold
5.87%
Upside
Reiterated
10/10/25
Barclays
$373→$395
Buy
13.02%
Upside
Reiterated
10/09/25
Mizuho Securities
$342→$420
Buy
20.18%
Upside
Reiterated
10/08/25
Guggenheim
$360→$398
Buy
13.88%
Upside
Reiterated
10/08/25
Wells Fargo
$330→$412
Buy
17.89%
Upside
Reiterated
10/06/25
TR | OpenAI - 4o
$342→$349
Buy
-0.14%
Downside
Reiterated
09/19/25
AI Generated ArticleAI Generated Article
TD Cowen
$315.77→$330
Buy
-5.58%
Downside
Reiterated
09/18/25
UBS
$425
Buy
21.61%
Upside
Reiterated
09/08/25
Elevance Health: Positive Outlook with Strategic Pricing and Growth Opportunities Justify Buy RatingWe had a chance to catch up with ELV following the company's commentary at an investor conference on 9/4 (our note here). Regarding the nonrecurring items being reported in 2025 EPS, ELV provided a general sizing of each of the components. A favorable tax item to be recorded in the 4th quarter of this year is the largest unusual item and represents more than $1 of EPS. The VBC provider settlement, which was booked in 2Q25, is sized at around $0.70, while an investment income benefit booked in 1Q25 contributes another $0.30. There is also some operating expense favorability that is not expected to recur in 2026. Altogether, these components lead to an EPS benefit in the high $2 range and rounds roughly to $3. Separate from this, the company noted incentive comp is expected to be a slight headwind for 2026 relative to where 2025 will ultimately land.
Robert W. Baird
―
Hold
―
Reiterated
08/14/25
J.P. Morgan
$472→$384
Buy
9.87%
Upside
Reiterated
07/22/25
Best Analysts Covering Elevance Health
1 Month
xxx
Success Rate
16/27 ratings generated profit
Average Return
+1.63%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +1.63% per trade.
3 Months
xxx
Success Rate
17/30 ratings generated profit
Average Return
-1.40%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.67% of your transactions generating a profit, with an average return of -1.40% per trade.
1 Year
2 Years
xxx
Success Rate
26/30 ratings generated profit
Average Return
+40.07%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +40.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ELV Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
1
6
6
5
0
Buy
38
31
29
36
26
Hold
4
7
8
8
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
43
44
43
49
30
Each month's total comprises the sum of three months' worth of ratings.
ELV Financial Forecast
ELV Stock Forecast FAQ
What is ELV’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health’s 12-month average price target is 376.24.
What is ELV’s upside potential, based on the analysts’ average price target?
Elevance Health has 7.65% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ELV a Buy, Sell or Hold?
Elevance Health has a consensus rating of Moderate Buy which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.
What is Elevance Health’s price target?
The average price target for Elevance Health is 376.24. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $425.00 ,the lowest forecast is $310.00. The average price target represents 7.65% Increase from the current price of $349.49.
The highest analyst price target is $425.00 ,the lowest forecast is $310.00. The average price target represents 7.65% Increase from the current price of $349.49.
What do analysts say about Elevance Health?
Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of ELV?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.